About Ocugen Inc
- Industry: Biotechnology
- Exchange: NASDAQ NMS - GLOBAL MARKET
- Country: US
- Website: https://ocugen.com/
Frequently Asked Questions
What is the 52-week range for OCGN?
The 52-week high is $2.725 and the 52-week low is $0.97.
What is the P/E ratio for OCGN?
The P/E ratio data is currently unavailable.
What is the dividend yield for OCGN?
This company does not currently pay a dividend or the data is unavailable.
What is the Return on Equity (ROE)?
The trailing twelve months (TTM) Return on Equity is -1306.71%.
What is the Net Profit Margin?
The Net Profit Margin (TTM) is -1343.08%.
What is the Price to Book (P/B) Ratio?
The annual Price to Book ratio stands at 7.91.
Analyst Recommendation Trends
Wall Street analyst consensus for OCGN over the last few months:
Latest OCGN News
Ocugen to Participate in Upcoming Scientific Conferences
MALVERN, Pa., Sept. 30, 2026 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a pioneering biotechnology company developing gene therapies for blindness diseases, today announced that the Company will present on its innovative modifier gene therapy platform at upcoming scientific conferences. Euretina Innovation Spotlight (EIS) 2026Location: VIECON, Vienna, AustriaDate: Wednesday, September 30, 2026Time: 2:34 p.m. CESTFormat: Company presentationTitle: Ocugen Company Over
Retinitis Pigmentosa Market Outlook to Strengthen During the Forecast Period (2026-2036) with Growing Focus on Disease-Modifying Therapies | DelveInsight
Recently published Retinitis Pigmentosa Market Insights report includes a comprehensive understanding of current treatment practices, retinitis pigmentosa emerging drugs, market share of individual therapies, and current and forecasted market size from 2022 to 2036, segmented into leading markets [the United States, the EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan].
Ocugen to Participate in Upcoming October Investor and Industry Conferences
MALVERN, Pa., Sept. 29, 2026 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a pioneering biotechnology company developing gene therapies for blindness diseases, today announced that members of its executive leadership team will present at two upcoming investor and industry conferences. H.C. Wainwright: Biotech on Tap 2026Location: EY Auditorium, Munich, GermanyDate: Thursday, October 1, 2026Time: 1:45–2:30 p.m. CESTFormat: Panel discussionTitle: Structured Finance Solut
Sector Update: Healthcare Stocks Edge Higher in Afternoon Trading
Healthcare stocks edged higher Friday afternoon, with the NYSE Healthcare Index and the State Street
Ocugen Eyes Global Access For Gene Therapy After Bahamas Boost — First Eye Disorder Patient Could Be Treated Within 90 Days
Ocugen is building an international pathway for OCU400 ahead of key Phase 3 data and a planned U.S. regulatory filing next year.
Ocugen Receives Provisional Approval and Priority Designation Under the Longevity and Regenerative Therapies Act in The Bahamas to Provide OCU400 to Patients for Treatment of Retinitis Pigmentosa
Ocugen will provide its investigational modifier gene therapy OCU400 through an expanded access program (EAP), with the goal of enabling the first patient to be treated for retinitis pigmentosa (RP) within 90 days, following full approval by the Longevity and Regenerative Therapies Board (LARTA Board)In partnership with the LARTA Board, Ocugen intends to address global access and unmet need through commercial pricing evidenced with cost-effectiveness for a one-time broad treatment of RPA novel m
Ocugen Receives Bahamas Regulator Provisional Approval For OCU400 Has Been Granted Approval And Priority Designation; The Company Will Supply OCU400 Through An EAP, With Goal Of Treating First RP Patient Within 90 Days
Ocugen will provide its investigational modifier gene therapy OCU400 through an expanded access program (EAP), with the goal of enabling the first patient to be treated for retinitis pigmentosa (RP) within 90 days,
Ocugen Targets Three Gene Therapy BLA Filings as Retinal Pipeline Advances
Ocugen (NASDAQ:OCGN) is preparing for three planned biologics license application, or BLA, submissions tied to late-stage gene therapy programs targeting retinal diseases, Chairman, Chief Executive Officer and Co-Founder Shankar Musunuri said during a company discussion. The company expects top-lin
Ocugen: Q3 Data Catalyst In Stargardt Disease Feels Critical
Ocugen is advancing three gene therapy programs targeting major unmet needs in ophthalmology. Click here to read more on why OCGN gets a Buy rating.
Ocugen: My Hold Rating Continued On OCU410ST Advancement And Upcoming Catalysts
Ocugen is maintained at a Hold rating due to mixed clinical progress and ongoing pivotal trials across its ophthalmology pipeline. Click for this OCGN update.
What's Happening With Ocugen Stock Thursday?
Shares of Ocugen are remaining flat Thursday morning as investors continue to weigh disappointing interim clinical trial data.
HC Wainwright & Co. Maintains Buy on Ocugen, Lowers Price Target to $9.5
HC Wainwright & Co. analyst Swayampakula Ramakanth maintains Ocugen (NASDAQ:OCGN) with a Buy and lowers the price target from $10 to $9.5.
12 Health Care Stocks Moving In Wednesday's After-Market Session
Gainers EXoZymes (NASDAQ:EXOZ) stock increased by 7.5% to $7.18 during Wednesday's after-market session. The market value of their outstanding shares is at $58.5 million. AEON Biopharma (AMEX:AEON) shares rose
12 Health Care Stocks Moving In Wednesday's Intraday Session
Gainers Opus Genetics (NASDAQ:IRD) shares increased by 31.7% to $5.71 during Wednesday's regular session. The company's market cap stands at $361.0 million. bioAffinity Technologies (NASDAQ:BIAF) stock
Related Stocks (Peers)
Recent Insider Transactions
| Date | Name | Shares Changed | Price | Value |
|---|---|---|---|---|
| 2026-09-09 | Musunuri Shankar | -57,264 | $1.12 | $64,136 |
| 2026-09-09 | Musunuri Shankar | -468,727 | $1.12 | $524,974 |
| 2026-06-15 | Johnson-Greene Treerita Essalima | +21,000 | $1.23 | $25,830 |
| 2026-06-11 | Kompella Uday | +170,100 | - | - |
| 2026-06-11 | Chandrasekhar Satishchandran | +170,100 | - | - |
| 2026-06-11 | Castillo Kirsten | +170,100 | - | - |
| 2026-06-11 | Zhang Junge | +170,100 | - | - |
| 2026-06-11 | Coleman Blaise | +170,100 | - | - |
| 2026-04-01 | Zhang Junge | -66,929 | - | - |
| 2026-04-01 | Zhang Junge | -112,205 | - | - |
| 2026-04-01 | Zhang Junge | -15,000 | - | - |
| 2026-04-01 | Zhang Junge | +66,929 | $1.42 | $95,039 |
| 2026-04-01 | Zhang Junge | +112,205 | $0.46 | $51,614 |
| 2026-04-01 | Zhang Junge | +15,000 | $0.51 | $7,650 |
| 2026-01-02 | Musunuri Shankar | +3,123,201 | - | - |
| 2026-01-02 | Musunuri Shankar | +3,123,201 | - | - |
| 2026-01-02 | Ramachandran Ramesh | +310,950 | - | - |
| 2026-01-02 | Ramachandran Ramesh | +207,300 | - | - |